EIF2AK3 and ovarian cancer: Combination of IRE-1 inhibitor KIRA6 with paclitaxel reduced cell death, while combination with the PERK inhibitor GSK2656157 led to no change or slight increase in cell death (Supplementary Figure 8), indicating that the two pathways might have different roles in mediating the response to paclitaxel in these ovarian cancer cell lines (Figure 5 and Supplementary Figure 8).